Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study

[1]  Ali I. Al-Gareeb,et al.  Covid-19 and development of heart failure: mystery and truth , 2021, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  A. Gundlapalli,et al.  Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data — United States, March 2020–January 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[3]  R. Menshawey,et al.  Contemporary approach to understand and manage COVID-19-related arrhythmia , 2021, The Egyptian Heart Journal.

[4]  A. McArthur,et al.  Evolutionary trajectory of SARS-CoV-2 and emerging variants , 2021, Virology journal.

[5]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[6]  J. Tregoning,et al.  Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape , 2021, Nature reviews. Immunology.

[7]  Samuel M. Brown,et al.  Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States , 2021, medRxiv.

[8]  Swapnil V Patel,et al.  COVID‐19 induced bradyarrhythmia and relative bradycardia: An overview , 2021, Journal of arrhythmia.

[9]  Y. Gupta,et al.  Hydroxychloroquine for SARS CoV2 Prophylaxis in Healthcare Workers - A Multicentric Cohort Study Assessing Effectiveness and Safety. , 2021, The Journal of the Association of Physicians of India.

[10]  R. Mittal,et al.  Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19 , 2021, Journal of family medicine and primary care.

[11]  David T. Huang,et al.  Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection , 2021, Open forum infectious diseases.

[12]  R. Perez-Padilla,et al.  Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial , 2021, medRxiv.

[13]  P. Taylor,et al.  Neutralizing monoclonal antibodies for treatment of COVID-19 , 2021, Nature Reviews Immunology.

[14]  A. Cook,et al.  Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial , 2021, International Journal of Infectious Diseases.

[15]  J. Sankar,et al.  Risk factors and frequency of COVID-19 among healthcare workers at a tertiary care centre in India: a case–control study , 2021, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[16]  B. Medhi,et al.  Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 , 2021, Annals of Internal Medicine.

[17]  S. Kalkanis,et al.  Association Between Implementation of a Universal Face Mask Policy for Healthcare Workers in a Health Care System and SARS-CoV-2 Positivity Testing Rate in Healthcare Workers , 2021, Journal of occupational and environmental medicine.

[18]  C. Prodromos,et al.  Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). , 2020, Reviews in cardiovascular medicine.

[19]  O. Nanni,et al.  Hydroxychloroquine as Prophylaxis for COVID-19: A Review , 2020, Frontiers in Pharmacology.

[20]  C. Tebé,et al.  A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 , 2020, The New England journal of medicine.

[21]  J. Balko,et al.  Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  P. Villablanca,et al.  Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19 , 2020, Current cardiology reviews.

[23]  H. Risch,et al.  Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis , 2020, medRxiv.

[24]  D. Raoult.  Lancet gate: a matter of fact or a matter of concern , 2020, New Microbes and New Infections.

[25]  S. Lofgren,et al.  Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19 , 2020, medRxiv.

[26]  P. Fournier,et al.  Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world , 2020, New Microbes and New Infections.

[27]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[28]  Amit N. Patel,et al.  Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[29]  K. Alexander,et al.  Effectiveness of Oseltamivir Prophylaxis in Influenza Outbreaks in Residential Aged Care , 2020, Journal of epidemiology and global health.

[30]  David R. Holtgrave,et al.  Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State , 2020, The Journal of Emergency Medicine.

[31]  T. Spector,et al.  Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study , 2020, medRxiv : the preprint server for health sciences.

[32]  J. Hardin,et al.  Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19 , 2020, Med.

[33]  P. Triggianese,et al.  The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 , 2020, Journal of Autoimmunity.

[34]  N. Sinha,et al.  Hydroxychloroquine and COVID-19 , 2020, Postgraduate Medical Journal.

[35]  Zhìhóng Hú,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[36]  Gengfu Xiao,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[37]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[38]  M. Matsuoka,et al.  Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. , 2015, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[39]  L. Leibovici,et al.  Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. , 2011, The Journal of antimicrobial chemotherapy.

[40]  Marc Van Ranst,et al.  In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine , 2004, Biochemical and Biophysical Research Communications.

[41]  A. Inglot.  Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. , 1969, The Journal of general virology.

[42]  Editor-in-Chief R. Seifert,et al.  Naunyn-Schmiedeberg's archives of pharmacology , 2005, Klinische Wochenschrift.

[43]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.